Basal insulin in the age of innovation: are diamonds still forever?
While modern therapies are increasingly prioritized due to superior efficacy, safety, and weight benefits, basal insulin remains indispensable for patients with advanced β-cell failure, symptomatic hyperglycemia, or contraindications to newer agents. Personalized, pathophysiology-driven strategies should guide therapy selection, including the integration of basal insulin where appropriate.
Authors
- Theocharis Koufakis (ORCID: https://orcid.org/0000-0002-5853-1352)
- Djordje S. Popovic (ORCID: https://orcid.org/0000-0002-2763-1326)
- Dimitrios Patoulias (ORCID: https://orcid.org/0000-0002-6899-684X)
- Vasileios Tsimihodimos
Institutions
- University of Novi Sad (RS)
- University of Ioannina (GR)
- Aristotle University of Thessaloniki (GR)
Publication Details
- Journal
- Expert Review of Endocrinology & Metabolism
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1080/17446651.2025.2580629
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00